Clinical Trials & Research

Search for Clinical Trials

Search Trials

USOR 13092 A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). CC-122-DLBCL-001.

Disease Types: Lymphoma
Available at: Niles


A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL.) USOR 17050/GO39942. Contact Project Manager Status.

Disease Types: Lymphoma
Available at: Arlington Heights, Niles


NEWLY OPENED TO ENROLLMENT: USOR 17093/CITADEL-205 A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Ka Inhibitor, In Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205) - INCB050465-205.

Disease Types: Lymphoma
Available at: Arlington Heights, Niles


NEW: OPEN TO ENROLLMENT - Study #16023, An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments (IMMU-132-05)

Disease Types: Breast
Available at: Arlington Heights, Niles


NOW OPEN: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen. USOR 17081 (C16038) Ph4 Ixazomib+Lena & Dex MM (MM-6)

Disease Types: Multiple Myeloma
Available at: Arlington Heights, Niles


NEW Randomized, Multi-Center, Open-Label, Phase 3, Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination with Oxaliplatin Plus Fluoropyrimidine vs. Oxaliplatin Plus Fluoropyrimidine in Subjects with Previously Untreated, Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer. USOR 16164 (BMS CA 209-649)

Disease Types: Gastric, Gastric/Gastroesophageal
Available at: Arlington Heights, Niles


Phase 2, NEW Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated, Unresectable, Locally Advanced or Metastatic HER2+ Breast Carcinoma. USOR 16195 (STAR ONT 380 206)

Disease Types: Breast
Available at: Arlington Heights, Niles


NEW: A Randomized, Open-Label, Phase 3 Study for Patients With Node-Positive, Early Stage, HR+, HER2-, Breast Cancer. MonarchE is a Phase 3 Study of Abemaciclib Combined with Standard Adjuvant EndocrineTherapy vs Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer. USOR 17082 (I3Y-MC-JPCF) (Monarche)

Disease Types: Breast
Available at: Arlington Heights, Niles


NEW Screening Protocol for STAR USOR 16248: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects with Diffuse Large B Cell Lymphoma. (USOR 17041)

Disease Types: Lymphoma
Available at: Arlington Heights, Niles


An Open-Label, Multicenter, Phase I/II Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) As A Single Agent In Subjects With Advanced Solid Tumors Or With B Cell Lymphomas And Tazemetostat In Combination With Prednisolone In Subjects With Relapsed Or Refractory Diffuse Large B Cell Lymphoma Or Follicular Lymphoma. USOR 16248 (STAR Ph 1/2 Tazemetostot r/r DLBCL+FL)

Disease Types: Lymphoma
Available at: Arlington Heights, Niles


A Phase Ib/II Clinical Study of BBI608 in Combination with Sorafenib or BBI503 in Combination with Sorafenib in Adult Patients with Hepatocellular Carcinoma. (HCC) USOR 14148 (PhIb/II BBI608/503+Sorafenib) Histologically or cytologically confirmed hepatocellular carcinoma that is metastatic, unresectable, or recurrent. No previous systemic anti-cancer treatment, though previous loco-regional therapy is allowed.

Disease Types: Hepatocellular, Liver
Available at: Arlington Heights, Niles


AN OPEN-LABEL PHASE 2 MULTI-COHORT TRIAL OF NIVOLUMAB IN ADVANCED OR METASTATIC MALIGNANCIES. HOLDING. CONTACT RESEARCH FOR OPEN COHORTS. USOR 16041 (CA 209-627)

Disease Types: Solid Tumor
Available at: Arlington Heights, Niles


AGIOS A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects 18 Years of Age and Older, with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation. (AG120-C-009)

Disease Types: Leukemia
Available at: Arlington Heights, Niles


2nd Line A Phase II/III, Biomarker-Driven Master Protocol For Previously Treated Squamous Cell Lung Cancer. - A Phase II Study of Talazoparib in Patients with Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer. - A Phase III Randomized Study of Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients with Stage IV Squamous Lung Cancer and No Matching Biomarker. (ECOG-ACRIN S1400)

Disease Types: Lung - Non-Small Cell Lung
Available at: Arlington Heights, Niles


A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib vs Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein. (ECOG-ACRIN 4512)

Disease Types: Lung - Non-Small Cell Lung
Available at: Arlington Heights, Niles


A Phase III, Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL Negative B Lineage Acute Lymphoblastic Leukemia in Adults. (ECOG-ACRIN 1910)

Disease Types: Leukemia
Available at: Arlington Heights, Niles


A Phase III, Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer. (ECOG-ACRIN S1207)

Disease Types: Breast
Available at: Arlington Heights, Niles


A Randomized, Phase III Post-Operative Trial of Platinum Base Chemotherapy vs Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Therapy. (ECOG-ACRIN 1131)

Disease Types: Breast
Available at: Arlington Heights, Niles


GRAIL - THE CIRCULATING CELL-FREE GENOME ATLAS (CCGA) STUDY. A Prospective, Multi-Center, Observational Study with Collections of De-Identified Biospecimens and Clinical Data from at Least 10,000 Participants from Clinical Networks in the United States, Canada and the United Kingdom. Next Generation Sequencing (NGS) based assay(s) of Nucleic Acids (NAs) Isolated From Peripheral Blood and Tumor Tissues. USOR 16140 (GRAIL-001)

Disease Types: Solid Tumor
Available at: Arlington Heights, Niles


A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy USOR 16251 (KEYNOTE-564)

Disease Types: Renal
Available at: Arlington Heights, Niles


A Multicenter, Open-Label, Randomized, Phase 3 Trial To Compare The Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma. USOR 16145 (E7080-G000-307)

Disease Types: Renal
Available at: Arlington Heights, Niles


Prospective Observational Study in Patients with Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine TumorsTreated with Lanreotide Depot in a U.S. Community Oncology Setting. USOR 15051 (Ipsen A-US-52030340)

Disease Types: Neuroendocrine
Available at: Arlington Heights, Niles


Registry - A Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients - The Insight MM Study. USOR 16035 (NSMM-5001)

Disease Types: Multiple Myeloma
Available at: Arlington Heights, Niles


2nd/3rd Line - A Phase 3B Randomized Study of Lenalidomide Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. USOR 13064 (CC-5013-NHL-008)

Disease Types: Lymphoma
Available at: Arlington Heights, Niles


Relapsed/Refractory A Phase 2b, Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma. USOR 16065 (UTX-TGR-205)

Disease Types: Lymphoma
Available at: Arlington Heights, Niles


1st Line - A Phase 2, Single-Arm, Open-Label Study of Single-Agent Brentuximab Vedotin for Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above. USOR 11282 (SGN35-015)

Disease Types: Lymphoma
Available at: Arlington Heights, Niles


Hodgkins Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices. USOR 16100 (CA20965)

Disease Types: Lymphoma
Available at: Arlington Heights, Niles


A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240mg Every 2 Weeks vs Nivolumab 480mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer who Received up to 12 Months of Nivolumab at 3mg/kg or 240mg Every 2 Weeks. USOR 15203 (CheckMate384-CA209384)

Disease Types: Lung - Non-Small Cell Lung
Available at: Arlington Heights, Niles


CA209-817- A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer. USOR 16156 (CA209-817)

Disease Types: Lung - Non-Small Cell Lung
Available at: Arlington Heights, Niles


Randomized, Open-Label, Phase 3 Trial of Nivolumab and Ipilimumab Versus Platinum-Doublet Chemotherapy in Early Stage NSCLC. USOR 16161 (CA209-816)

Disease Types: Lung - Non-Small Cell Lung
Available at: Arlington Heights, Niles


Polaris: Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study. USOR 16128 (A5481081)

Disease Types: Breast
Available at: Arlington Heights, Niles


Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients with Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy. USOR 16097 (G1T28-04)

Disease Types: Breast
Available at: Arlington Heights, Niles


A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy Versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma. USO 16054 (MK3475-361)

Disease Types: Bladder
Available at: Arlington Heights, Niles


NEW: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONROLLED, MULTICENTER TRIAL, TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE IN PATIENTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC METASTATIC CASTRATE-RESISTANT PROSTATE CANCER WITH PTEN-LOSS (PTEN DIAGNOSTIC POSITIVE) TUMORS. USOR 16160 (ROCHE CO 39303)

Disease Types: Prostate
Available at: Arlington Heights, Niles


Primary Objective of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry will Collect Data to Evaluate Safety Data Specific to the Use of Solaris and to Characterize the Progression of PNH as well as Clinical Outcomes, Mortality and Morbidity in Solaris and Non-Solaris Treated Patients. Secondary Objective is Raising PNH Awareness in the Medical Community and Patient/Potential Patient Population. USOR 08160 (M07-001)

Disease Types: Hematology, PNH
Available at: Arlington Heights, Niles